Minapharm Pharmaceuticals (CAI:MIPH) Beneish M-Score: -2.83 (As of Jul. 13, 2026)


CAI:MIPH Minapharm Pharmaceuticals CAI:MIPH
41 GF Score
Price E£698.08
GF Value E£362.31
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Minapharm Pharmaceuticals Beneish M-Score?

Minapharm Pharmaceuticals CAI:MIPH -0.27% 41 Beneish M-Score is -2.83 as of Jul. 13, 2026. GuruFocus rates CAI:MIPH with a GF Score™ of 41/100 and a GF Value™ of E£362.31 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 911 Drug Manufacturers companies, Minapharm Pharmaceuticals ranks better than 77.06% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.83 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Minapharm Pharmaceuticals's Beneish M-Score or its related term are showing as below:

CAI:MIPH' s Beneish M-Score Range Over the Past 10 Years
Min: -2.83   Med: -2.45   Max: -2.21
Current: -2.83

During the past 5 years, the highest Beneish M-Score of Minapharm Pharmaceuticals was -2.21. The lowest was -2.83. And the median was -2.45.


Minapharm Pharmaceuticals Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Minapharm Pharmaceuticals's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Minapharm Pharmaceuticals Beneish M-Score Chart

Minapharm Pharmaceuticals Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
0.00 0.00 -2.45 -2.21 -2.83

Minapharm Pharmaceuticals Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.21 0.00 -2.10 -2.45 -2.83

CAI:MIPH vs ZTS, UTHR, VTRS: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Minapharm Pharmaceuticals's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Minapharm Pharmaceuticals Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Minapharm Pharmaceuticals's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Minapharm Pharmaceuticals's Beneish M-Score falls into.


CAI:MIPH
41GF Score
Minapharm Pharmaceuticals CAI:MIPH
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Minapharm Pharmaceuticals Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Minapharm Pharmaceuticals for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.6435+0.528 * 0.9657+0.404 * 0.9937+0.892 * 1.1497+0.115 * 0.8306
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.1336+4.679 * -0.032293-0.327 * 0.8106
=-2.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was E£747 Mil.
Revenue was 1598.112 + 1501.116 + 1731.8 + 1607.149 = E£6,438 Mil.
Gross Profit was 544.279 + 484.501 + 698.538 + 578.487 = E£2,306 Mil.
Total Current Assets was E£6,253 Mil.
Total Assets was E£13,148 Mil.
Property, Plant and Equipment(Net PPE) was E£6,243 Mil.
Depreciation, Depletion and Amortization(DDA) was E£380 Mil.
Selling, General, & Admin. Expense(SGA) was E£1,159 Mil.
Total Current Liabilities was E£4,807 Mil.
Long-Term Debt & Capital Lease Obligation was E£1,763 Mil.
Net Income was -14.636 + 16.846 + 39.961 + -1.956 = E£40 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = E£0 Mil.
Cash Flow from Operations was 230.81 + -68.128 + 378.642 + -76.519 = E£465 Mil.
Total Receivables was E£1,010 Mil.
Revenue was 2019.283 + 1512.966 + 1083.089 + 984.327 = E£5,600 Mil.
Gross Profit was 866.135 + 578.247 + 270.841 + 221.409 = E£1,937 Mil.
Total Current Assets was E£5,717 Mil.
Total Assets was E£12,003 Mil.
Property, Plant and Equipment(Net PPE) was E£5,687 Mil.
Depreciation, Depletion and Amortization(DDA) was E£285 Mil.
Selling, General, & Admin. Expense(SGA) was E£889 Mil.
Total Current Liabilities was E£4,587 Mil.
Long-Term Debt & Capital Lease Obligation was E£2,812 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(747.339 / 6438.177) / (1010.096 / 5599.665)
=0.116079 / 0.180385
=0.6435

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1936.632 / 5599.665) / (2305.805 / 6438.177)
=0.345848 / 0.358146
=0.9657

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (6252.689 + 6242.644) / 13148.14) / (1 - (5716.987 + 5686.58) / 12003.296)
=0.04965 / 0.049964
=0.9937

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=6438.177 / 5599.665
=1.1497

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(284.708 / (284.708 + 5686.58)) / (380.18 / (380.18 + 6242.644))
=0.047679 / 0.057405
=0.8306

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(1158.843 / 6438.177) / (889.09 / 5599.665)
=0.179996 / 0.158776
=1.1336

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((1762.999 + 4807.024) / 13148.14) / ((2812.44 + 4586.786) / 12003.296)
=0.499692 / 0.616433
=0.8106

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(40.215 - 0 - 464.805) / 13148.14
=-0.032293

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Minapharm Pharmaceuticals has a M-score of -2.83 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.83 mean?
Minapharm Pharmaceuticals (CAI:MIPH) has a Beneish M-Score of -2.83 as of Jul. 13, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Minapharm Pharmaceuticals and its competitors. According to the industry distribution chart, Minapharm Pharmaceuticals ranks #209 out of 911 companies in the Drug Manufacturers industry, placing it in the top 22.9%.
Is Minapharm Pharmaceuticals' Beneish M-Score too high?
Minapharm Pharmaceuticals' current Beneish M-Score is -2.83. Based on the distribution chart, Minapharm Pharmaceuticals ranks #209 out of 911 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Minapharm Pharmaceuticals has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Minapharm Pharmaceuticals' Beneish M-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Minapharm Pharmaceuticals ranks #209 out of 911 companies for Beneish M-Score. This places Minapharm Pharmaceuticals in the top 23% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Minapharm Pharmaceuticals and its competitors. Minapharm Pharmaceuticals's current Beneish M-Score is -2.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Minapharm Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Minapharm Pharmaceuticals (CAI:MIPH) is currently considered Significantly Overvalued. The stock's GF Value™ is E£362.31, compared to a current price of E£698.08 — trading 92.7% above its estimated fair value. The current Beneish M-Score is -2.83. Minapharm Pharmaceuticals' overall GF Score™ is 41/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Minapharm Pharmaceuticals (CAI:MIPH), the current Beneish M-Score is -2.83 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Minapharm Pharmaceuticals (CAI:MIPH) Overvalued in 2026?

Based on GuruFocus' analysis, Minapharm Pharmaceuticals stock appears to be overvalued. The current stock price of E£698.08 is trading 92.7% above its estimated GF Value™ of E£362.31. GuruFocus considers Minapharm Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for CAI:MIPH:

  • Beneish M-Score: -2.83
  • GF Value™: E£362.31 vs. price of E£698.08 (92.7% above fair value)
  • GF Score™: 41/100 with 10 warning signs

No single metric tells the full story. See the CAI:MIPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Minapharm Pharmaceuticals Business Description

Address El-Bardissi Street, 2T Takseem Asmaa Fahmy Street, Heliopolis, Cairo, EGY
Minapharm Pharmaceuticals is a company whose purpose is to produce medicines and chemicals. medical supplies. cosmetics, veterinary medicines, dental supplies, and the production of dietary supplements and herbal medicines. It produces drugs for many segments such as biogenetics, orthopedic, ophthalmology, miscellaneous, dermatology, gastroenterology, cardiology, and uro-gynaecology lines.
41GF Score

Get the complete analysis for CAI:MIPH

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

E£698.08
Price
E£362.31
GF Value